{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:01:39Z","timestamp":1786122099299,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001287","name":"The Elsa U Pardee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:43:30Z","timestamp":1777074210000},"page":"958.e1-958.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers"],"prefix":"10.1016","volume":"32","author":[{"given":"Justin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Lisath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Srisuwananukorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas Sankarnaga","family":"Devarakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Emily","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Mohammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don Michael","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7840","authenticated-orcid":false,"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.04.009_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100750","article-title":"How I treat diffuse large B-cell lymphoma","volume":"8","author":"Melchardt","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtct.2026.04.009_bib0002","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2024025482","article-title":"How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor","volume":"146","author":"Shadman","year":"2025","journal-title":"Blood"},{"issue":"10272","key":"10.1016\/j.jtct.2026.04.009_bib0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.009_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","article-title":"Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data","volume":"62","author":"Braunlin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.jtct.2026.04.009_bib0005","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1002\/cam4.3237","article-title":"Recent survival trends in diffuse large B-cell lymphoma\u2013\u2013have we made any progress beyond rituximab?","volume":"9","author":"Epperla","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.009_bib0006","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/s41375-020-01061-9","article-title":"Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome","volume":"35","author":"Barnea Slonim","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.009_bib0007","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.009_bib0008","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-022-00680-y","article-title":"Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.009_bib0009","doi-asserted-by":"crossref","first-page":"205.e1","DOI":"10.1016\/j.jtct.2023.06.015","article-title":"Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation","volume":"30","author":"Yalniz","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.009_bib0010","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdx160","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"29","author":"Musto","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.009_bib0011","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.009_bib0012","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2026.04.009_bib0013","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.009_bib0014","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/cancers14030519","article-title":"Second cancers in classical Hodgkin lymphoma and diffuse large B-cell lymphoma: a systematic review by the Fondazione Italiana Linfomi","volume":"14","author":"Nassi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.009_bib0015","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/cam4.5139","article-title":"Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality","volume":"12","author":"Parsons","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.009_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-023-00784-z","article-title":"Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019","volume":"13","author":"van der Straten","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.009_bib0017","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41588-024-01755-1","article-title":"Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis","volume":"56","author":"Bernstein","year":"2024","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.jtct.2026.04.009_bib0018","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2026.04.009_bib0019","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.009_bib0020","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.009_bib0021","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180069","article-title":"Distinct landscape and clinical implications of therapy-related clonal hematopoiesis","volume":"134","author":"Takahashi","year":"2024","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.009_bib0022","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.009_bib0023","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.009_bib0024","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.009_bib0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.009_bib0026","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.009_bib0027","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.009_bib0028","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41588-025-02250-x","article-title":"Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy","volume":"57","author":"Liu","year":"2025","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.009_bib0029","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/ajh.70014","article-title":"Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders","volume":"100","author":"Esai Selvan","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.009_bib0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2026.04.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.009_bib0032","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.009_bib0033","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtct.2024.06.027","article-title":"Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma","volume":"30","author":"Lorenc","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.009_bib0034","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-025-01676-4","article-title":"Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies","volume":"18","author":"Umyarova","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.009_bib0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41375-021-01320-3","article-title":"Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length","volume":"36","author":"Boyle","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.009_bib0036","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/2767-9764.CRC-23-0093","article-title":"Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma","volume":"3","author":"Mouhieddine","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.009_bib0037","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2024026236","article-title":"Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes","volume":"146","author":"Lionetti","year":"2025","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2026.04.009_bib0038","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1182\/bloodadvances.2024013414","article-title":"Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia","volume":"8","author":"Vijenthira","year":"2024","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2026.04.009_bib0039","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.009_bib0040","first-page":"2176","article-title":"Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphoma","volume":"110","author":"Iglesias","year":"2025","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jtct.2026.04.009_bib0041","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/bloodadvances.2019000731","article-title":"Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias","volume":"3","author":"Sridharan","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.009_bib0042","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2643-3230.BCD-23-0106","article-title":"Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis","volume":"5","author":"Saygin","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.009_bib0043","first-page":"2076","article-title":"Overall cancer risk in people with deleterious germline DDX41 variants","volume":"110","author":"Korotev","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.009_bib0044","first-page":"1126","article-title":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","volume":"110","author":"Sobas","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.009_bib0045","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:44:08Z","timestamp":1786088648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726002708"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}